Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc.
Your view on AURX
Overview
What the company does, where it operates, and who runs it.
About Nuo Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David E. Jorden
- Headquarters
- 8285 El Rio, Houston, TX, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David E. Jorden
- Headquarters
- 8285 El Rio, Houston, TX, US
Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market.
The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nuo Therapeutics, Inc., and the rating behind it. AURX last traded at $1.50; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nuo Therapeutics, Inc.. Starting points for Nuo Therapeutics, Inc.: EPS -$0.04, beta -104.09 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nuo Therapeutics, Inc.. Nuo Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nuo Therapeutics, Inc.. Trailing twelve-month EPS for Nuo Therapeutics, Inc. stands at -$0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nuo Therapeutics, Inc.. Nuo Therapeutics, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nuo Therapeutics, Inc. valued side by side against its closest peers. Nuo Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nuo Therapeutics, Inc., and how their positions are changing. At a $72.4M market value, institutional positions materially move Nuo Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nuo Therapeutics, Inc. executives and directors. Shares of Nuo Therapeutics, Inc. have traded between $1.00 and $3.23 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nuo Therapeutics, Inc.. Nuo Therapeutics, Inc. is a $72.4M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nuo Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nuo Therapeutics, Inc.. Coverage tracks Nuo Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.